Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00063427 | Study Evaluating MAC-321 in Colorectal Cancer | PHASE2 | COMPLETED | 45 | — | — | - | Feb 1, 2004 | Aug 21, 2009 | - | — |
| Name | Type | Description |
|---|---|---|
| MAC-321 | DRUG | - |
Inclusion Criteria: * Histologic and/or cytologic diagnosis of metastatic or relapsed colorectal cancer at any time during disease but not candidates for surgical resection. * Prior treatment with at least 1 conventional approved therapeutic regimen. * Subjects who have failed prior cytotoxic chemo...